https://stock.noler.com/us/stock/plx-pharma-winddown-corp https://stock.noler.com/us/stock/plx-pharma-winddown-corp/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/accounts-receivable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/accrued-professional-fees-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/accumulated-depreciation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/acquisition-consideration-transferred-equity-interests-issued-and-issuable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/advertising-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/amortization-of-financing-costs-and-discounts https://stock.noler.com/us/stock/plx-pharma-winddown-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/asset-impairment-charges https://stock.noler.com/us/stock/plx-pharma-winddown-corp/basic-shares https://stock.noler.com/us/stock/plx-pharma-winddown-corp/capital-expenditures https://stock.noler.com/us/stock/plx-pharma-winddown-corp/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-acquired-from-acquisition https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-and-equivalents https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-and-restricted-cash https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-and-restricted-cash-including-disposal-group-and-discontinued-operations https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-flow-breakdown https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cash-uninsured-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/plx-pharma-winddown-corp/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/plx-pharma-winddown-corp/class-of-warrant-or-right-outstanding https://stock.noler.com/us/stock/plx-pharma-winddown-corp/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/plx-pharma-winddown-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/plx-pharma-winddown-corp/common-stock-value https://stock.noler.com/us/stock/plx-pharma-winddown-corp/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/plx-pharma-winddown-corp/contract-with-customer-asset-gross https://stock.noler.com/us/stock/plx-pharma-winddown-corp/contract-with-customer-asset-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/plx-pharma-winddown-corp/conversion-of-stock-shares-converted https://stock.noler.com/us/stock/plx-pharma-winddown-corp/conversion-of-stock-shares-issued https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cost-of-revenue https://stock.noler.com/us/stock/plx-pharma-winddown-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/plx-pharma-winddown-corp/current-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/current-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/current-portion-of-long-term-debt https://stock.noler.com/us/stock/plx-pharma-winddown-corp/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/customer-deposits-noncurrent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/debt-face-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/debt-issuance-costs-incurred-during-noncash-or-partial-noncash-transaction https://stock.noler.com/us/stock/plx-pharma-winddown-corp/debt-repaid https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-costs-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-income-tax-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-revenue-noncurrent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-gross https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-other https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-other-loss-carryforwards https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deposit-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deposits-assets-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/deposits-assets-noncurrent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/depreciation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/depreciation-and-amortization https://stock.noler.com/us/stock/plx-pharma-winddown-corp/derivative-liabilities-noncurrent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/diluted-shares https://stock.noler.com/us/stock/plx-pharma-winddown-corp/dilutive-securities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/dilutive-shares https://stock.noler.com/us/stock/plx-pharma-winddown-corp/dividends-common-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/dividends-preferred-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/dividends-preferred-stock-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/plx-pharma-winddown-corp/effective-tax-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/eps https://stock.noler.com/us/stock/plx-pharma-winddown-corp/eps-basic https://stock.noler.com/us/stock/plx-pharma-winddown-corp/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/plx-pharma-winddown-corp/federal-income-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/finance-lease-liability https://stock.noler.com/us/stock/plx-pharma-winddown-corp/financing-cash-flow https://stock.noler.com/us/stock/plx-pharma-winddown-corp/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/plx-pharma-winddown-corp/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/plx-pharma-winddown-corp/form-d-other https://stock.noler.com/us/stock/plx-pharma-winddown-corp/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/general-and-administrative-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/goodwill https://stock.noler.com/us/stock/plx-pharma-winddown-corp/goodwill-impaired-accumulated-impairment-loss https://stock.noler.com/us/stock/plx-pharma-winddown-corp/goodwill-impairment-loss https://stock.noler.com/us/stock/plx-pharma-winddown-corp/gross-profit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/impairment-of-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/plx-pharma-winddown-corp/impairment-of-intangible-assets-indefinitelived-excluding-goodwill https://stock.noler.com/us/stock/plx-pharma-winddown-corp/income-tax https://stock.noler.com/us/stock/plx-pharma-winddown-corp/income-tax-expense-benefit-adjustment-of-deferred-tax-asset-liability https://stock.noler.com/us/stock/plx-pharma-winddown-corp/income-taxes-paid https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-accrued-interest-receivable-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-inventories https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-operating-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-other-operating-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-prepaid-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/increase-decrease-in-security-deposits https://stock.noler.com/us/stock/plx-pharma-winddown-corp/incremental-common-shares-attributable-to-call-options-and-warrants https://stock.noler.com/us/stock/plx-pharma-winddown-corp/incremental-common-shares-attributable-to-conversion-of-preferred-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/plx-pharma-winddown-corp/indefinite-lived-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/plx-pharma-winddown-corp/insider-transactions-preferred https://stock.noler.com/us/stock/plx-pharma-winddown-corp/insider-transactions-preferred/purchases https://stock.noler.com/us/stock/plx-pharma-winddown-corp/insider-transactions-stock-options https://stock.noler.com/us/stock/plx-pharma-winddown-corp/insider-transactions-warrants https://stock.noler.com/us/stock/plx-pharma-winddown-corp/insider-transactions-warrants/purchases https://stock.noler.com/us/stock/plx-pharma-winddown-corp/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/plx-pharma-winddown-corp/intangible-assets-net-including-goodwill https://stock.noler.com/us/stock/plx-pharma-winddown-corp/interest-expense-on-debt https://stock.noler.com/us/stock/plx-pharma-winddown-corp/interest-income-expense-nonoperating-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/interest-paid-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/interest-payable-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/interest-receivable-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/inventory https://stock.noler.com/us/stock/plx-pharma-winddown-corp/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/plx-pharma-winddown-corp/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/plx-pharma-winddown-corp/inventory-valuation-reserves https://stock.noler.com/us/stock/plx-pharma-winddown-corp/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/plx-pharma-winddown-corp/inventory-write-down https://stock.noler.com/us/stock/plx-pharma-winddown-corp/investing-cash-flow https://stock.noler.com/us/stock/plx-pharma-winddown-corp/investment-income-interest https://stock.noler.com/us/stock/plx-pharma-winddown-corp/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/plx-pharma-winddown-corp/lease-cost https://stock.noler.com/us/stock/plx-pharma-winddown-corp/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/plx-pharma-winddown-corp/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/liability-for-uncertain-tax-positions-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/licenses-revenue https://stock.noler.com/us/stock/plx-pharma-winddown-corp/loans-receivable-basis-spread-on-variable-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/loans-receivable-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/long-term-debt https://stock.noler.com/us/stock/plx-pharma-winddown-corp/members-equity https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-cash-from https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-cash-from-financing-activities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-cash-from-investing-activities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-cash-from-operating-activities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-change-in-cash https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-income https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/plx-pharma-winddown-corp/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/plx-pharma-winddown-corp/notes-and-loans-receivable-net-noncurrent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/number-of-defendants https://stock.noler.com/us/stock/plx-pharma-winddown-corp/number-of-operating-segments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/number-of-reporting-units https://stock.noler.com/us/stock/plx-pharma-winddown-corp/officers-compensation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-cash-flow https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-expenses https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-income https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-cost https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-liability https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-liability-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-2 https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-leases-future-minimum-payments-receivable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-leases-future-minimum-payments-receivable-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-leases-future-minimum-payments-receivable-in-three-years https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-leases-future-minimum-payments-receivable-in-two-years https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-leases-rent-expense-net https://stock.noler.com/us/stock/plx-pharma-winddown-corp/operating-loss-carryforwards https://stock.noler.com/us/stock/plx-pharma-winddown-corp/other-current-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/other-income https://stock.noler.com/us/stock/plx-pharma-winddown-corp/other-noncurrent-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/other-noncurrent-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/paid-in-capital-dividends-in-excess-of-retained-earnings https://stock.noler.com/us/stock/plx-pharma-winddown-corp/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/plx-pharma-winddown-corp/paid-in-kind-interest https://stock.noler.com/us/stock/plx-pharma-winddown-corp/payments-to-acquire-machinery-and-equipment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/payments-to-acquire-notes-receivable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/payments-to-acquire-short-term-investments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-shares-facts https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-dividends-and-other-adjustments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-dividends-income-statement-impact https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/plx-pharma-winddown-corp/preferred-stock-value https://stock.noler.com/us/stock/plx-pharma-winddown-corp/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/prepaid-expense-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/pretax-income https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-convertible-debt https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-issuance-of-preferred-stock-and-preference-stock https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-issuance-or-sale-of-equity https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-notes-payable https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-sale-of-short-term-investments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/plx-pharma-winddown-corp/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/plx-pharma-winddown-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/plx-pharma-winddown-corp/property-plant-equipment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/public-float https://stock.noler.com/us/stock/plx-pharma-winddown-corp/receivables-net-current https://stock.noler.com/us/stock/plx-pharma-winddown-corp/related-party-transaction-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/plx-pharma-winddown-corp/repayments-of-debt https://stock.noler.com/us/stock/plx-pharma-winddown-corp/research-and-development https://stock.noler.com/us/stock/plx-pharma-winddown-corp/research-and-development-expense-excluding-acquired-in-process-cost https://stock.noler.com/us/stock/plx-pharma-winddown-corp/research-and-development-in-process https://stock.noler.com/us/stock/plx-pharma-winddown-corp/retained-earnings https://stock.noler.com/us/stock/plx-pharma-winddown-corp/revenue https://stock.noler.com/us/stock/plx-pharma-winddown-corp/revenue-from-contract-with-customer-including-assessed-tax https://stock.noler.com/us/stock/plx-pharma-winddown-corp/revenue-from-grants https://stock.noler.com/us/stock/plx-pharma-winddown-corp/revenue-remaining-performance-obligation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/security-deposit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/sga-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/share-based-goods-and-nonemployee-services-transaction-stockholders-equity https://stock.noler.com/us/stock/plx-pharma-winddown-corp/share-price https://stock.noler.com/us/stock/plx-pharma-winddown-corp/shareholders-equity https://stock.noler.com/us/stock/plx-pharma-winddown-corp/shares-authorized https://stock.noler.com/us/stock/plx-pharma-winddown-corp/shares-issued https://stock.noler.com/us/stock/plx-pharma-winddown-corp/shares-issued-shares-new-issues https://stock.noler.com/us/stock/plx-pharma-winddown-corp/short-term-investments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-award-vesting-rights-percentage https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-rsu-forfeited-in-period https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-rsu-grants-in-period https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-rsu-nonvested-number https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-award-rsu-vested-in-period https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-based-compensation https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-shares-issued-shares-issued-for-services https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-shares-issued-value-issued-for-services https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-shares-issued-value-share-based-compensation-gross https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-exercisable-number https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-options-vested-number-of-shares https://stock.noler.com/us/stock/plx-pharma-winddown-corp/stock-split-ratio https://stock.noler.com/us/stock/plx-pharma-winddown-corp/sublease-income https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-credit-carryforward-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-prior-year-income-taxes https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/plx-pharma-winddown-corp/tax-reconciliation-nondeductible-expense-other https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-accretion-to-redemption-value-adjustment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-dividends-adjustment https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-liquidation-preference https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-par-or-stated-value-per-share https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-shares-authorized https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-shares-issued https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-shares-outstanding https://stock.noler.com/us/stock/plx-pharma-winddown-corp/temporary-equity-value-excluding-additional-paid-in-capital https://stock.noler.com/us/stock/plx-pharma-winddown-corp/total-assets https://stock.noler.com/us/stock/plx-pharma-winddown-corp/total-contract-liability https://stock.noler.com/us/stock/plx-pharma-winddown-corp/total-liabilities https://stock.noler.com/us/stock/plx-pharma-winddown-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/plx-pharma-winddown-corp/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/plx-pharma-winddown-corp/variable-lease-cost https://stock.noler.com/us/stock/plx-pharma-winddown-corp/weighted-average-number-of-share-outstanding-basic-and-diluted